Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women

Inclusion Criteria: * Have the ability to understand and provide informed consent by signing the informed consent form (non-illiterate). * Have the ability to comply with protocol requirements, such as attending scheduled visits and responding to follow-up phone calls. * Prior enrollment in the 311-HPV-1003 study, with at least one dose of the study vaccine administered. * At least one documented gynecological visit between 6 and 48 months during the previous 311-HPV-1003 study. * Refrain from vaginal intercourse for 48 hours and avoid behaviors such as vaginal douching or using vaginal medications that could interfere with gynecological examinations or sample collection for 72 hours prior to each gynecological visit. Exclusion Criteria: * Participants who received another HPV vaccine during the prior 311-HPV-1003 study or between the end of that study and enrollment in this extension study. * Participants diagnosed with HPV 16- or 18-related CIN2+ by an independent pathology expert panel during the prior 311-HPV-1003 study, or who were definitively diagnosed with HPV 16- or 18-related CIN2+ through external testing after the prior study ended. * Participants who, at baseline in the 311-HPV-1003 study, tested positive for both HPV 16 and 18 antibodies, or were positive for both HPV 16 and 18 (by Cobas 4800), or whose cytology was not normal or of low-grade changes. * Participants who are pregnant at the time of gynecological visits or within three months prior to the visit. * Participants with any other factors deemed unsuitable for participation in the clinical trial, as determined by the investigator.